A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo

International Journal of Oncology

Volumn 39, Issue 2, 2011, Pages 401-408

  Rastelli, Luca ^a,d   Valentino, Maria Luisa ^b   Minderman, Melissa Corso ^a,e   Landin, Judith ^a,f   Malyankar, Uriel M ^a,g   Lescoe, Mary K ^a,h   Kitson, Richard ^a   Brunson, Kenneth ^a   Souan, Lina ^a,i   Forenza, Salvatore ^a,c   Goldfarb, Ronald H ^a,c   Rabbani, Shafaat A ^b  

^a Sopherion Therapeutics Inc   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Sopherion Therapeutics Inc   (United States)

^d EMD SERONO INC   (United States)

^e A Roche Company   (United States)

^f Thompson CT School System   (United States)

^g MannKind Corporation   (United States)

^h PFIZER INC   (United States)

ⁱ KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Angiogenesis; KDR; Melanoma; Peptide; Tumor metastasis

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE DERIVATIVE; ST 100038; ST 100045; ST 100059; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL LINE; CELL SURVIVAL; ENDOTHELIAL CELLS; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959989554     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1040     Document Type: Article

References (30)

1. Cliff WJ Martin JD and Michael CA: Use of ear chamber with uterine muscle transplant to differentiate myometrial and vascular activity. Nature 199: 399-400, 1963.
2. Schoefl GI: Studies on inflammation. III. Growing capillaries: their structure and permeability. Virchows Arch Pathol Anat Physiol Klin Med 337: 97-141, 1963.
3. Ausprunk DH and Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65, 1977 (Pubitemid 8153798)
4. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S and Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47: 149-161, 2003. (Pubitemid 37279152)
5. Hendrix MJ Seftor EA, Hess AR and Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421, 2003. (Pubitemid 37328845)
6. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC and Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249-8255, 2004 (Pubitemid 39491762)
7. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280: C1358-C1366, 2001.
8. Ahmed SI, Thomas AL and Steward WP: Vascular endothelial growth factor (VEGF) inhibition by small molecules. J. Chemother 16 (Suppl 4): 59-63, 2004 (Pubitemid 40065284)
9. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004 (Pubitemid 38618122)
10. Zhu Z and Witte L: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17: 195-212, 1999 (Pubitemid 30037954)
11. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G and Mazie JC: Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19: 1525-1533, 2000. (Pubitemid 30182160)
12. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ Bungay PM and Stetler-Stevenson WG: Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 162: 1431-1439, 2003. (Pubitemid 36512825)
13. Pasco S, Ramont L, Venteo L, Maquart FX and Monboisse JC: In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res 301: 251-265, 2004
14. Qiu H, Orr FW, Jensen D, Wang HH, Mcintosh AR, Hasinoff BB, Nance DM, Pylypas S, Qi K, Song C, Muschel RJ and Al-Mehdi AB: Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. Am J Pathol 162: 403-412, 2003. (Pubitemid 36267848)
15. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D and Rabbani SA: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101: 1345-1356, 2004 (Pubitemid 39180390)
16. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L and Zhu Z: Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278: 43496-43507, 2003. (Pubitemid 37345973)
17. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J and Roberts DD: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100: 1423-1431, 1999. (Pubitemid 29451703)
18. Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, De Vos A and Gerritsen ME: Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-I receptors. Arterioscler Thromb Vasc Biol 22: 1797-1803, 2002. (Pubitemid 35315764)
19. Landon LA, Zou J and Deutscher SL: Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol 1: 113-132, 2004
20. Sato A and Sone S: A peptide mimetic of human interferon (IFN)-beta. Biochem J 371: 603-608, 2003. (Pubitemid 36547646)
21. Bonetto S, Carlavan I and Baty D: Isolation and characterization of antagonist and agonist peptides to the human melanocortin 1 receptor. Peptides 26: 2302-2313, 2005 (Pubitemid 41584099)
22. Koolpe M, Burgess R, Dail M and Pasquale EB: EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem 280: 17301-17311, 2005. (Pubitemid 41389199)
23. An P, Lei H, Zhang J, Song S, He L, Jin G, Liu X, Wu J, Meng L, Liu M and Shou C: Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 111: 165-173, 2004
24. Khachatourians GG, Clark DJ, Adler HI and Hardigree AA: Cell growth and division in Escherichia coli: a common genetic control involved in cell division and minicell formation. J Bacteriol 116: 226-229, 1973.
25. Makowski L: Structural constraints on the display of foreign peptides on filamentous bacteriophages. Gene 128: 5-11, 1993.
26. Wilson DR and Finlay BB: Phage display: applications, innovations, and issues in phage and host biology. Can J Microbiol 44: 313-329, 1998.
27. Zachary I: VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31: 1171-1177, 2003.
28. Fischer PM: The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 4: 339-356, 2003.
29. Chorev M: The partial retro-inverso modification: a road traveled together. Biopolymers 80: 67-84, 2005
30. Damiano V, Melisi D, Bianco C, Raben D, Caputo R Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S, Ciardiello F and Tortora G: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11: 5639-5644, 2005